Related Experiment Video
Updated: Jul 29, 2026
10:08
Purification and Aggregation of the Amyloid Precursor Protein Intracellular Domain
Published on: August 28, 2012
Processing of Alzheimer's disease-associated beta-amyloid precursor protein
N N Dewji1, E R Shelton, M J Adler
1Department of Medicine, School of Medicine, University of California, San Diego, La Jolla 94304.
Journal of Molecular Neuroscience : MN
|January 1, 1990
Summary
Researchers studied Alzheimer's disease-associated beta-amyloid precursor protein processing. Key differences were found between intracellular and secreted forms, with distinct fragments generated.
Area of Science:
- Neuroscience
- Molecular Biology
- Cell Biology
Background:
- Alzheimer's disease is linked to beta-amyloid precursor protein (APP) processing.
- Understanding APP processing is crucial for neurodegenerative disease research.
- Distinct processing pathways may exist for intracellular and secreted APP.
Purpose of the Study:
- To investigate the processing of Alzheimer's disease-associated beta-amyloid precursor protein.
- To compare the processing of intracellular versus secreted forms of APP.
- To identify stable processed fragments of APP.
Main Methods:
- Cell culture studies using normal human fibroblasts and a human neuroblastoma cell line.
- Pulse-chase experiments to track protein processing over time.
- Immunoprecipitation using antibodies against the A4 region of APP.
Main Results:
- Significant differences observed in the processing of intracellular and secreted APP.
- Intracellular APP undergoes amino-terminal processing into smaller fragments.
- Secreted APP shows no further proteolytic cleavage after release; a 6,000 Mr fragment is postulated as the A4-carrying remnant.
Conclusions:
- A 33,000 Mr fragment containing the A4 region is a stable end-product of intracellular APP processing.
- Posttranslational modifications likely dictate differential processing of intracellular and secreted APP.
- These findings contribute to understanding APP metabolism in Alzheimer's disease.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...